Table 3 Relative risks (RRs) and 95% confidence intervals (CIs) of recurrence (R+), lymph node involvement (LN+), lymphovascular space invasion (LVSI+), and myometrial invasion over 50% (MI > 50%) in patients with DFF40*-, DFF45**-, and BCL2***-negative endometrial cancers
| Â | Low and moderate-grade endometroid cancer (Group A) | Non-endometrioid and high-grade endometroid endometrial cancer (Group B) | Total cohort |
|---|---|---|---|
R+ | |||
 DFF40* | 1.611 (CI:0.694-3.741; p = 0.267) | 7.423 (CI: 1.048-52.599; p = 0.046) | 2.435 (CI: 1.365-4.343; p = 0.002) |
 DFF45** | 0.892 (CI:0.222-3.581; p = 0.871) | 1.843 (CI: 0.608-5.586; p = 0.280) | 1.211 (CI:0.506-2.898; p = 0.668) |
 BCL-2*** | 2.048 (CI: 0.821-5.081; p = 0.121) | 12.847 (CI: 1.805-91.464; p = 0.012) | 4.192 (CI: 2.128-8.261; p < 0.001) |
LN+ | |||
 DFF40* | 1.033 (CI:0.567-1.766; p = 0.915) | 7.422 (CI:1.048-52.594; p = 0.045) | 4.19 (CI: 1.88-9.33; p < 0.001) |
 DFF45** | 0.433 (CI:0.133-1.412; p = 0.166) | 1.161 (CI: 0.441-3.060; p = 0.763) | 0.70 (CI: 0.33-1.48; p = 0.344) |
 BCL-2*** | 3.386 (CI:1.256-9.127; p = 0.015) | 3.624 (CI:1.493-11.424; p-0.028) | 4.36 (CI: 2.14-8.87; p < 0.001) |
LVSI+ | |||
 DFF40* | 0.947 (CI: 0.508-1.767; p = 0.865) | 2907 (CI: 1.273-6.641; p = 0.011) | 1.953 (CI:1.360-2.803;p < 0.001) |
 DFF45** | 0.844 (CI: 0.374-1.907; p = 0.684) | 1.736 (CI: 0.846-3.563; p = 0.133) | 1.378 (CI: 0.749-2.537; p = 0.303) |
 BCL-2*** | 2.483 (CI: 1.459-4.226; p < 0.001) | 3.624 (CI:1.493-11.424; p-0.028) | 3.089 (CI:2.075-4.599; p < 0.001) |
MI > 50% | |||
 DFF40* | 1.058 (CI: 0.873-1.283; p = 0.562) | 1.183 (CI:0.962-1.456; p = 0.112) | 1.216 (CI: 1.078-1.270; p = 0.001) |
 DFF45** | 1.057 (CI: 0.668-1.672; p = 0.812) | 1.189 (CI: 0.895-1.580; p = 0.233) | 1.086 (CI: 0.888-1.328; p = 0.422) |
 BCL-2*** | 1.335 (CI: 1.332-1.574; p < 0.001) | 1.073 (CI: 0.920-1.251; p = 0.369) | 1.549 (CI: 1.346-1.782; p < 0.001) |